Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes
Increased circulating sclerostin and accumulation of advanced glycation end‐products (AGEs) are two potential mechanisms underlying low bone turnover and increased fracture risk in type 2 diabetes (T2D). Whether the expression of the sclerostin‐encoding SOST gene is altered in T2D, and whether it is...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2020
|
| _version_ | 1797069317618008064 |
|---|---|
| author | Piccoli, A Cannata, F Strollo, R Pedone, C Leanza, G Russo, F Greto, V Isgrò, C Quattrocchi, CC Massaroni, C Silvestri, S Vadalà, G Bisogno, T Denaro, V Pozzilli, P Tang, SJ Silva, MJ Conte, C Papalia, R Maccarrone, M Napoli, N |
| author_facet | Piccoli, A Cannata, F Strollo, R Pedone, C Leanza, G Russo, F Greto, V Isgrò, C Quattrocchi, CC Massaroni, C Silvestri, S Vadalà, G Bisogno, T Denaro, V Pozzilli, P Tang, SJ Silva, MJ Conte, C Papalia, R Maccarrone, M Napoli, N |
| author_sort | Piccoli, A |
| collection | OXFORD |
| description | Increased circulating sclerostin and accumulation of advanced glycation end‐products (AGEs) are two potential mechanisms underlying low bone turnover and increased fracture risk in type 2 diabetes (T2D). Whether the expression of the sclerostin‐encoding SOST gene is altered in T2D, and whether it is associated with AGEs accumulation or regulation of other bone formation‐related genes is unknown. We hypothesized that AGEs accumulate and SOST gene expression is upregulated in bones from subjects with T2D, leading to downregulation of bone forming genes (RUNX2 and osteocalcin) and impaired bone microarchitecture and strength. We obtained bone tissue from femoral heads of 19 T2D postmenopausal women (mean HbA1c 6.5%) and 73 age‐ and BMI‐comparable non‐diabetic women undergoing hip replacement surgery. Despite similar bone mineral density (BMD) and biomechanical properties, we found a significantly higher SOST (p=0.006) and a parallel lower RUNX2 (p=0.025) expression in T2D compared with non‐diabetic subjects. Osteocalcin gene expression did not differ between T2D and non‐diabetic subjects, as well as circulating osteocalcin and sclerostin levels. We found a 1.5‐fold increase in total bone AGEs content in T2D compared with non‐diabetic women (364.8±78.2 vs. 209.9±34.4 μg quinine/g collagen, respectively; p<0.001). AGEs bone content correlated with worse bone microarchitecture, including lower volumetric BMD (r=‐0.633; p=0.02), BV/TV (r=‐0.59; p=0.033) and increased trabecular separation/spacing (r= 0.624; p=0.023). In conclusion, our data show that even in patients with good glycemic control, T2D affects the expression of genes controlling bone formation (SOST and RUNX2). We also found that accumulation of AGEs is associated with impaired bone microarchitecture. We provide novel insights that may help understand the mechanisms underlying bone fragility in T2D. |
| first_indexed | 2024-03-06T22:22:39Z |
| format | Journal article |
| id | oxford-uuid:5597aa92-9282-4afd-9100-9a3e51cbd5a3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:22:39Z |
| publishDate | 2020 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:5597aa92-9282-4afd-9100-9a3e51cbd5a32022-03-26T16:44:57ZSclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5597aa92-9282-4afd-9100-9a3e51cbd5a3EnglishSymplectic ElementsWiley2020Piccoli, ACannata, FStrollo, RPedone, CLeanza, GRusso, FGreto, VIsgrò, CQuattrocchi, CCMassaroni, CSilvestri, SVadalà, GBisogno, TDenaro, VPozzilli, PTang, SJSilva, MJConte, CPapalia, RMaccarrone, MNapoli, NIncreased circulating sclerostin and accumulation of advanced glycation end‐products (AGEs) are two potential mechanisms underlying low bone turnover and increased fracture risk in type 2 diabetes (T2D). Whether the expression of the sclerostin‐encoding SOST gene is altered in T2D, and whether it is associated with AGEs accumulation or regulation of other bone formation‐related genes is unknown. We hypothesized that AGEs accumulate and SOST gene expression is upregulated in bones from subjects with T2D, leading to downregulation of bone forming genes (RUNX2 and osteocalcin) and impaired bone microarchitecture and strength. We obtained bone tissue from femoral heads of 19 T2D postmenopausal women (mean HbA1c 6.5%) and 73 age‐ and BMI‐comparable non‐diabetic women undergoing hip replacement surgery. Despite similar bone mineral density (BMD) and biomechanical properties, we found a significantly higher SOST (p=0.006) and a parallel lower RUNX2 (p=0.025) expression in T2D compared with non‐diabetic subjects. Osteocalcin gene expression did not differ between T2D and non‐diabetic subjects, as well as circulating osteocalcin and sclerostin levels. We found a 1.5‐fold increase in total bone AGEs content in T2D compared with non‐diabetic women (364.8±78.2 vs. 209.9±34.4 μg quinine/g collagen, respectively; p<0.001). AGEs bone content correlated with worse bone microarchitecture, including lower volumetric BMD (r=‐0.633; p=0.02), BV/TV (r=‐0.59; p=0.033) and increased trabecular separation/spacing (r= 0.624; p=0.023). In conclusion, our data show that even in patients with good glycemic control, T2D affects the expression of genes controlling bone formation (SOST and RUNX2). We also found that accumulation of AGEs is associated with impaired bone microarchitecture. We provide novel insights that may help understand the mechanisms underlying bone fragility in T2D. |
| spellingShingle | Piccoli, A Cannata, F Strollo, R Pedone, C Leanza, G Russo, F Greto, V Isgrò, C Quattrocchi, CC Massaroni, C Silvestri, S Vadalà, G Bisogno, T Denaro, V Pozzilli, P Tang, SJ Silva, MJ Conte, C Papalia, R Maccarrone, M Napoli, N Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title | Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title_full | Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title_fullStr | Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title_full_unstemmed | Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title_short | Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes |
| title_sort | sclerostin regulation microarchitecture and advanced glycation end products in the bone of elderly women with type 2 diabetes |
| work_keys_str_mv | AT piccolia sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT cannataf sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT strollor sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT pedonec sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT leanzag sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT russof sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT gretov sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT isgroc sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT quattrocchicc sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT massaronic sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT silvestris sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT vadalag sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT bisognot sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT denarov sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT pozzillip sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT tangsj sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT silvamj sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT contec sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT papaliar sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT maccarronem sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes AT napolin sclerostinregulationmicroarchitectureandadvancedglycationendproductsintheboneofelderlywomenwithtype2diabetes |